OPEN ACCESS Freely available online

Journal of Food: Microbiology, Safety & Hygiene

Opinion Article

Bioactive Potential of *Lactococcus lactis* Metabolites against Lipopolysaccharide

Li Xingchun*

Department of Food Science, Carleton University, Ottawa, Canada

DESCRIPTION

Lactococcus lactis, a Gram-positive bacterium widely recognized for its role in the dairy industry, has recently garnered attention beyond its traditional applications. Research into its metabolites has revealed optimistic bioactive properties, particularly in combating the effects of Lipopolysaccharide (LPS), a potent endotoxin produced by Gram-negative bacteria. This article explores the scientific insights into how *Lactococcus lactis* metabolites interact with LPS and their potential therapeutic applications.

Lipopolysaccharide, also known as endotoxin, is a key component of the outer membrane of Gram-negative bacteria. Structurally, LPS consists of lipid A, core polysaccharide, and O antigen, with lipid A being the toxic component responsible for triggering inflammatory responses in mammalian hosts. Upon exposure to LPS, immune cells such as macrophages and monocytes recognize lipid A through Toll-Like Receptor 4 (TLR4), initiating a cascade of immune responses that can lead to inflammation, sepsis, and even septic shock in severe cases.

Role of *Lactococcus lactis*

Lactococcus lactis, a non-pathogenic and Generally Regarded as Safe (GRAS) bacterium, has been extensively studied for its metabolic capabilities and probiotic properties. It naturally produces various metabolites during fermentation, some of which exhibit bioactive properties. These metabolites have shown potential in modulating immune responses and mitigating inflammatory pathways, making *Lactococcus lactis* an attractive candidate for therapeutic applications against LPS-induced toxicity.

Mechanisms of action against LPS

Anti-inflammatory properties: Studies have demonstrated that metabolites from *Lactococcus lactis* can attenuate pro-inflammatory cytokine production triggered by LPS. For instance, certain peptides and proteins derived from *Lactococcus lactis* fermentation exhibit anti-inflammatory effects by inhibiting NF-κB signaling pathways or modulating cytokine expression profiles.

Direct binding and neutralization: Some metabolites may directly bind to lipid A or other components of LPS, thereby neutralizing its toxicity. This interaction prevents LPS from interacting with TLR4 receptors on immune cells, thereby reducing the initiation of inflammatory responses.

Immune modulation: *Lactococcus lactis* metabolites can also influence immune cell function and polarization. They may promote regulatory T cell responses or enhance phagocytic activity, thereby contributing to the resolution of inflammation and the restoration of immune homeostasis following LPS exposure.

Bioactive metabolites of *Lactococcus lactis*

Exopolysaccharides: These are complex carbohydrates produced by *Lactococcus lactis* during fermentation. Exopolysaccharides have been shown to possess immunomodulatory properties, influencing cytokine production and macrophage activity.

Peptides and proteins: Certain peptides and proteins derived from *Lactococcus lactis* fermentation exhibit antioxidant and anti-inflammatory activities. These bioactive molecules can scavenge Reactive Oxygen Species (ROS) and inhibit inflammatory mediators, thereby protecting cells from LPS-induced oxidative stress and damage.

Lactic acid: As a major metabolic byproduct of *Lactococcus lactis* fermentation, lactic acid contributes to the acidic environment that inhibits the growth of pathogenic bacteria. Additionally, lactic acid has been shown to modulate immune responses and promote intestinal barrier function, which could indirectly mitigate LPS-induced inflammation.

Therapeutic potential and applications

Gastrointestinal health: *Lactococcus lactis* and its metabolites are of particular interest in maintaining gastrointestinal health. By modulating gut microbiota composition and enhancing mucosal

Correspondence to: Li Xingchun, Department of Food Science, Carleton University, Ottawa, Canada, E-mail: xuzhou22@edu.ge

Received: 12-Jul-2024, Manuscript No. JFMSH-24-32526; **Editor assigned:** 15-Jul-2024, PreQC No. JFMSH-24-32526 (PQ); **Reviewed:** 29-Jul-2024, QC No. JFMSH-24-32526; **Revised:** 05-Aug-2024, Manuscript No. JFMSH-24-32526 (R); **Published:** 12-Aug-2024, DOI: 10.35841/2476-2059.24.9.301.

Citation: Xingchun L (2024). Bioactive Potential of *Lactococcus lactis* Metabolites against Lipopolysaccharide. J Food Microbial Saf Hyg. 9:301.

barrier function, these metabolites can reduce the translocation of LPS from the gut into systemic circulation, thereby preventing systemic inflammatory responses.

Sepsis and septic shock: Given the ability of LPS to induce severe inflammatory responses leading to sepsis and septic shock, therapeutic strategies utilizing *Lactococcus lactis* metabolites could potentially mitigate these life-threatening conditions. By targeting LPS-induced inflammation at various stages of the immune response, these metabolites offer a multifaceted approach to managing sepsis.

Chronic inflammatory diseases: Conditions characterized by chronic inflammation, such as Inflammatory Bowel Disease (IBD) and rheumatoid arthritis, could benefit from interventions utilizing *Lactococcus lactis* metabolites. These metabolites have the potential to modulate immune dysregulation and alleviate symptoms associated with chronic inflammation.

While the therapeutic potential of *Lactococcus lactis* metabolites against LPS-induced toxicity is constant, several challenges remain. These include optimizing production methods to ensure consistent yield and bioactivity of metabolites, elucidating specific mechanisms of action *in vivo*, and conducting rigorous clinical trials to validate efficacy and safety in human subjects. Future research directions could focus on:

Precision medicine approaches: Tailoring *Lactococcus lactis* metabolite therapies based on individual immune profiles and disease states.

Synthetic biology: Engineering *Lactococcus lactis* strains to enhance production of specific bioactive metabolites with desired therapeutic properties.

Combination therapies: Exploring synergistic effects of *Lactococcus lactis* metabolites with conventional treatments to improve clinical outcomes.

CONCLUSION

In summary, *Lactococcus lactis* metabolites stand poised as a beacon of hope in the quest to combat the detrimental effects of LPS, paving the way for innovative approaches in immunotherapy and inflammation management. *Lactococcus lactis* metabolites represent an optimistic frontier in the field of bioactive compounds with therapeutic potential against LPS-induced toxicity. From their ability to modulate immune responses and mitigate inflammatory pathways to their application in managing sepsis and chronic inflammatory diseases, these metabolites offer diverse avenues for therapeutic intervention. Continued research and development efforts are essential to harnessing the full potential of *Lactococcus lactis* metabolites and translating them into effective clinical treatments for LPS-related disorders.